Strongbridge Biopharma plc (SBBP)

Etorro trading 970x250

About Strongbridge Biopharma plc

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing’s syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania. Address: 900 Northbrook Drive, Trevose, PA, United States, 19053

Strongbridge Biopharma plc News and around…

Latest news about Strongbridge Biopharma plc (SBBP) common stock and company :

Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
05 Oct, 2021 FinancialContent

Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings”). Strongbridge shares and Xeris shares ceased trading on the Nasdaq Global Select Market (“Nasdaq”) at the close of business today. Shares of Xeris Biopharma Holdings are expected to begin trading on the Nasdaq under the ticker symbol “XERS” on October 6, 2021.

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
14 Sep, 2021 FinancialContent

Gainers Xeris Pharmaceuticals (NASDAQ:XERS) stock rose 4.96% to $2.75 during Tuesday's after-market session. At the close, Xeris ...

Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
14 Sep, 2021 FinancialContent

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) (“Strongbridge”) by Xeris.

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
09 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
08 Sep, 2021 FinancialContent

Gainers Cardiff Oncology (NASDAQ:CRDF) shares increased by 24.68% to $8.79 during Wednesday's after-market session. ...

Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma
30 Aug, 2021 FinancialContent

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) today announced that a leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Xeris stockholders vote “FOR” all proposals related to the Company’s transaction with Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”).

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
17 Aug, 2021 FinancialContent

Gainers Forte Biosciences (NASDAQ:FBRX) stock increased by 16.38% to $27.7 during Tuesday's pre-market session. The ...

Stocks That Hit 52-Week Lows On Monday
16 Aug, 2021 FinancialContent

On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap ...

30 Stocks Moving in Thursday's Pre-Market Session
12 Aug, 2021 FinancialContent

Gainers Conifer Holdings, Inc. (NASDAQ: CNFR) shares rose 40.9% to $4.00 in pre-market trading after the company reported ...

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

STRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Strongbridge Biopharma plc - SB
28 May, 2021 FinancialContent

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Strongbridge Biopharma plc (NasdaqGS: SBBP) to Xeris Pharmaceuticals, Inc. (NasdaqGS: XERS). Under the terms of the proposed transaction, shareholders of Strongbridge will receive only 0.7840 shares of Xeris plus one contingent value right for each share of Strongbridge that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Looking Into Strongbridge Biopharma's Return On Capital Employed
27 May, 2021 FinancialContent

Strongbridge Biopharma (NASDAQ:SBBP) reported Q1 sales of $8.38 million. Earnings fell to a loss of $10.07 million, resulting in a 3.15% ...

Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
25 May, 2021 FinancialContent

Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first ...

52 Biggest Movers From Yesterday
25 May, 2021 FinancialContent

Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA ...

Strongbridge Biopharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Strongbridge Biopharma plc Is Fair to Shareholders; Investors Are Encouraged to Contact t
24 May, 2021 FinancialContent

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Strongbridge Biopharma plc (NASDAQ: SBBP) to Xeris Pharmaceuticals, Inc. is fair to Strongbridge shareholders. Under the terms of the merger, Strongbridge shareholders will receive 0.7840 shares of the combined company and 1 contingent value right (“CVR”) for each Strongbridge share that they own. The CVR is worth up to $1.00 in cash or stock of the combined company upon achievement of certain triggering events.

Mid-Afternoon Market Update: Dow Jumps 250 Points; Scopus BioPharma Shares Spike Higher
24 May, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded up 0.75% to 34,462.98 while the NASDAQ rose 1.64% to 13,691.64. The S&P also rose, ...

Why Strongbridge Biopharma's Stock Is Trading Higher Today
24 May, 2021 FinancialContent

Strongbridge Biopharma(NASDAQ:SBBP) shares are trading higher after Xeris Pharmaceuticals announced it will acquire the company in ...

12 Health Care Stocks Moving In Monday's Intraday Session
24 May, 2021 FinancialContent

Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 101.34% to $12.0 during Monday's regular session. As of 12:30 EST, ...

Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge
24 May, 2021 FinancialContent

Midway through trading Monday, the Dow traded up 0.58% to 34,405.22 while the NASDAQ rose 1.43% to 13,663.92. The S&P also rose, ...

35 Stocks Moving In Monday's Mid-Day Session
24 May, 2021 FinancialContent

Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares jumped 123.7% to $13.33 after the company reported the FDA approval of IND ...

Mid-Morning Market Update: Markets Open Higher; Xeris Pharmaceuticals To Acquire Strongbridge Biopharma
24 May, 2021 FinancialContent

Following the market opening Monday, the Dow traded up 0.50% to 34,378.59 while the NASDAQ rose 1.18% to 13,629.81. The S&P also ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
24 May, 2021 FinancialContent

Gainers Strongbridge Biopharma (NASDAQ:SBBP) stock moved upwards by 14.1% to $2.75 during Monday's pre-market ...

Strongbridge Shares Shoot Higher After Xeris' Buyout Deal At $267M
24 May, 2021 FinancialContent

Xeris Pharmaceuticals Inc(NASDAQ: XERS)has agreed to acquireStrongbridge Biopharma plc(NASDAQ:SBBP) for ...

Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
24 May, 2021 FinancialContent

Xeris Pharmaceuticals, Inc. (“Xeris”) (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, and Strongbridge Biopharma plc (“Strongbridge”) (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that they have entered into a definitive agreement under which Xeris will acquire Strongbridge for stock and contingent value rights (“CVRs”). The agreement, including the maximum aggregate amount payable under the CVRs, values Strongbridge at approximately $267 million based on the closing price of Xeris common stock of $3.47 on May 21, 2021 and Strongbridge’s fully diluted share capital. The transaction, which has been unanimously approved by the boards of directors of both companies, with the exception of Jeffrey W. Sherman, M.D., a director in common to both companies, who abstained from the voting, is expected to close early in the fourth quarter of 2021, subject to the satisfaction of closing conditions. Upon close of the transaction, the businesses of Xeris and Strongbridge will be combined under a new entity to be called Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings”).

Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
24 May, 2021 FinancialContent

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, and Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that they have entered into a definitive agreement under which Xeris will acquire Strongbridge for stock and contingent value rights (“CVRs”). The agreement, including the maximum aggregate amount payable under the CVRs, values Strongbridge at approximately $267 million based on the closing price of Xeris Shares of $3.47 on May 21, 2021 and Strongbridge's fully diluted share capital. The transaction, which has been unanimously approved by the boards of directors of both companies, with the exception of Jeffrey W. Sherman, M.D., a director in common to both companies, who abstained from the voting, is expected to close early in the fourth quarter of 2021, subject to the satisfaction of closing conditions. Upon close of the transaction, the businesses of Xeris and Strongbridge will be combined under a new entity to be called Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings”).

Analysts Anticipate 29% Upside For The Holdings of VTWG
14 May, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $263.83 per unit.

Strongbridge Bio's Recorlev US Application For Cushing's Syndrome Under Review, Potential Approval In Early 2022
13 May, 2021 FinancialContent

TheFDA has accepted to reviewStrongbridge Biopharma plc's(NASDAQ:SBBP) marketing application for Recorlev ...

Strongbridge Biopharma plc (SBBP) is a NASDAQ Common Stock listed in , ,

970x250